The ascendancy of Viagra and its influence on the drug landscape presents a complex question for investors. While the early sales figures were remarkable, the intellectual property has ended, leading to a flood of off-brand alternatives that are reducing revenue. Furthermore, the market is facing difficulties related to demographic trends and evolv